Neuvivo

Executive Summary

Neuvivo is a clinical-stage biotechnology company developing NP001, a novel immunotherapy for Amyotrophic Lateral Sclerosis (ALS). Unlike traditional approaches targeting neurons directly, NP001 aims to rebalance the innate immune system to reduce neuroinflammation, a key driver of motor neuron destruction. Based in Palo Alto, California, the company was founded in 2015 and is privately held. Its unique mechanism of action holds promise for addressing the urgent unmet need in ALS, where few disease-modifying therapies exist. Neuvivo's approach could potentially slow or halt disease progression by modulating the body's immune response at an early stage. While the company has not yet disclosed specific pipeline milestones, NP001 has shown encouraging signals in earlier trials, and the company is likely advancing toward pivotal studies or regulatory interactions.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 Clinical Trial Data Readout for NP001 in ALS40% success
• Q2 2026Pre-IND or End-of-Phase 2 Meeting with FDA70% success
• TBDPartnership or Licensing Deal for NP00130% success